Evaxion A/S
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $EVAX in the last 30 days.
See all $EVAX insider activity →Evaxion A/S (EVAX), a clinical-stage TechBio company, is nearing a key milestone with its AI-designed personalized cancer vaccine, EVX-01. The vaccine is being evaluated in a Phase 2 trial in combination with Merck's (MRK) KEYTRUDA for advanced melanoma patients. Each patient receives a unique vaccine based on their individual biology.
Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.
Evaxion Biotech (EVAX) has expanded its AI-Immunology platform to target autoimmune diseases, adding to its focus on cancer and infectious diseases. The company is testing a tolerogenic vaccine and an autoantibody binder, with initial data to be presented at a summit in November 2026. Evaxion believes its platform could offer more effective and safer treatments than current options, potentially opening new partnerships and commercial opportunities.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EVAX (Evaxion A/S). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EVAX coverage spans earnings, financial news and technology.
The upcoming Phase 2 data could drive significant upside if results are positive, but uncertainty remains until data are released.
Positive trial data could lift EVAX as investors reassess the vaccine's efficacy and commercial potential.
Potential new therapeutic area could broaden market opportunity and attract partnerships.
Earnings beat expectations on loss reduction and cash runway, prompting modest price uptick.
Analyst upgrades may support short-term price appreciation.
AlphAI scores every news story that mentions EVAX with an AI model for sentiment and relevance, and aggregates insider trades from Evaxion A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evaxion A/S (EVAX), a clinical-stage TechBio company, is nearing a key milestone with its AI-designed personalized cancer vaccine, EVX-01. The vaccine is being evaluated in a Phase 2 trial in combination with Merck's (MRK) KEYTRUDA for advanced melanoma patients. Each patient receives a unique vaccine based on their individual biology.
1 min readEvaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.
2 min readEvaxion Biotech (EVAX) has expanded its AI-Immunology platform to target autoimmune diseases, adding to its focus on cancer and infectious diseases. The company is testing a tolerogenic vaccine and an autoantibody binder, with initial data to be presented at a summit in November 2026. Evaxion believes its platform could offer more effective and safer treatments than current options, potentially opening new partnerships and commercial opportunities.
1 min readEvaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.
2 min readAnalysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.
1 min readEvaxion A/S (EVAX) reported a Q2 2026 net loss of $3.7M, improving from the prior year. Cash reserves totaled $14M, extending runway into 2H 2027. The company advanced its cancer and infectious disease vaccine pipeline, with key data presentations and regulatory filings expected. EVAX stock rose 6.35% in pre-market trading.
2 min readEvaxion A/S (EVAX) reported Q2 2026 financial results, including a net loss of $3.7M. The company highlighted progress in its R&D pipeline, including upcoming data presentations for cancer vaccine candidates EVX-01, EVX-04, and EVX-05, as well as CMV vaccine EVX-V1. Evaxion also won the 2026 Prix Galien UK Award for Best digital health solution. The company expects its cash runway to extend into the second half of 2027.
3 min readEvaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides
2 min readEvaxion A/S (NASDAQ: EVAX) will release a business update and its Q2 2026 financial results on Aug. 20, 2026, before Nasdaq CM opens. Management will host a conference call and webcast at 14:30 CET/08:30 EST to present the update and results and take questions.
2 min readEvaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.
2 min read
